Fibrinolytic factors and risk of venous thrombosis
| Quartile of fibrinolytic factor . | 1 (reference) . | 2 . | 3 . | 4 . | Median (5th-95th percentile) . |
|---|---|---|---|---|---|
| Plasminogen (cutoff in %)* | 88 | 96 | 105 | ||
| No. patients | 131 | 180 | 209 | 250 | 99 (80%-126%) |
| No. control subjects | 188 | 187 | 185 | 182 | 96 (77%-128%) |
| OR for age and sex | 1 | 1.3 (1.0-1.8) | 1.5 (1.1-2.0) | 1.8 (1.4-2.5) | |
| OR for age, sex, and BMI | 1 | 1.2 (0.9-1.7) | 1.3 (1.0-1.8) | 1.6 (1.2-2.2) | |
| α2-antiplasmin (cutoff in %)* | 95 | 102 | 110 | ||
| No. patients | 175 | 179 | 205 | 211 | 104 (83%-123%) |
| No. control subjects | 197 | 197 | 183 | 165 | 102 (86%-120%) |
| OR for age and sex | 1 | 1.0 (0.8-1.3) | 1.2 (0.9-1.7) | 1.4 (1.0-1.9) | |
| OR for age, sex, and BMI | 1 | 1.0 (0.7-1.3) | 1.1 (0.8-1.5) | 1.2 (0.9-1.7) | |
| TAFI (cutoff in %)* | 106 | 117 | 127 | ||
| No. patients | 143 | 195 | 166 | 266 | 121 (93%-155%) |
| No. control subjects | 199 | 180 | 179 | 184 | 117 (92%-147%) |
| OR for age and sex | 1 | 1.4 (1.1-1.9) | 1.2 (0.9-1.7) | 1.8 (1.3-2.4) | |
| OR for age, sex, and BMI | 1 | 1.3 (1.0-1.8) | 1.1 (0.8-1.6) | 1.6 (1.2-2.1) | |
| PAI-1 (cutoff in ng/mL)* | 55 | 62 | 71 | ||
| No. patients | 148 | 169 | 120 | 332 | 146 (40-552) ng/mL |
| No. control subjects | 185 | 186 | 186 | 185 | 113 (36-401) ng/mL |
| OR for age and sex | 1 | 1.1 (0.8-1.5) | 0.8 (0.6-1.1) | 2.2 (1.6-2.9) | |
| OR for age, sex, and BMI | 1 | 1.1 (0.8-1.4) | 0.7 (0.5-0.9) | 1.6 (1.1-2.1) | |
| t-PA (cutoff in ng/mL)* | 4.8 | 6.1 | 7.8 | ||
| No. patients | 134 | 135 | 209 | 292 | 7.0 (3.8-12.0) ng/mL |
| No. control subjects | 185 | 186 | 186 | 185 | 6.1 (3.4-10.9) ng/mL |
| OR for age and sex | 1 | 1.0 (0.8-1.4) | 1.6 (1.2-2.2) | 2.3 (1.7-3.3) | |
| OR for age, sex, and BMI | 1 | 0.9 (0.7-1.3) | 1.3 (0.9-1.8) | 1.8 (1.3-2.6) |
| Quartile of fibrinolytic factor . | 1 (reference) . | 2 . | 3 . | 4 . | Median (5th-95th percentile) . |
|---|---|---|---|---|---|
| Plasminogen (cutoff in %)* | 88 | 96 | 105 | ||
| No. patients | 131 | 180 | 209 | 250 | 99 (80%-126%) |
| No. control subjects | 188 | 187 | 185 | 182 | 96 (77%-128%) |
| OR for age and sex | 1 | 1.3 (1.0-1.8) | 1.5 (1.1-2.0) | 1.8 (1.4-2.5) | |
| OR for age, sex, and BMI | 1 | 1.2 (0.9-1.7) | 1.3 (1.0-1.8) | 1.6 (1.2-2.2) | |
| α2-antiplasmin (cutoff in %)* | 95 | 102 | 110 | ||
| No. patients | 175 | 179 | 205 | 211 | 104 (83%-123%) |
| No. control subjects | 197 | 197 | 183 | 165 | 102 (86%-120%) |
| OR for age and sex | 1 | 1.0 (0.8-1.3) | 1.2 (0.9-1.7) | 1.4 (1.0-1.9) | |
| OR for age, sex, and BMI | 1 | 1.0 (0.7-1.3) | 1.1 (0.8-1.5) | 1.2 (0.9-1.7) | |
| TAFI (cutoff in %)* | 106 | 117 | 127 | ||
| No. patients | 143 | 195 | 166 | 266 | 121 (93%-155%) |
| No. control subjects | 199 | 180 | 179 | 184 | 117 (92%-147%) |
| OR for age and sex | 1 | 1.4 (1.1-1.9) | 1.2 (0.9-1.7) | 1.8 (1.3-2.4) | |
| OR for age, sex, and BMI | 1 | 1.3 (1.0-1.8) | 1.1 (0.8-1.6) | 1.6 (1.2-2.1) | |
| PAI-1 (cutoff in ng/mL)* | 55 | 62 | 71 | ||
| No. patients | 148 | 169 | 120 | 332 | 146 (40-552) ng/mL |
| No. control subjects | 185 | 186 | 186 | 185 | 113 (36-401) ng/mL |
| OR for age and sex | 1 | 1.1 (0.8-1.5) | 0.8 (0.6-1.1) | 2.2 (1.6-2.9) | |
| OR for age, sex, and BMI | 1 | 1.1 (0.8-1.4) | 0.7 (0.5-0.9) | 1.6 (1.1-2.1) | |
| t-PA (cutoff in ng/mL)* | 4.8 | 6.1 | 7.8 | ||
| No. patients | 134 | 135 | 209 | 292 | 7.0 (3.8-12.0) ng/mL |
| No. control subjects | 185 | 186 | 186 | 185 | 6.1 (3.4-10.9) ng/mL |
| OR for age and sex | 1 | 1.0 (0.8-1.4) | 1.6 (1.2-2.2) | 2.3 (1.7-3.3) | |
| OR for age, sex, and BMI | 1 | 0.9 (0.7-1.3) | 1.3 (0.9-1.8) | 1.8 (1.3-2.6) |
BMI indicates body mass index; OR, odds ratio; PAI-1 plasminogen activator inhibitor 1; TAFI, thrombin-activatable fibrinolysis inhibitor; and t-PA, tissue plasminogen activator.
PAI-1 levels were not measured in 1 patient; and TAFI, plasminogen, α2-antiplasmin, t-PA, and PAI-1 levels were not measured in 1 control subject.